Clinical Trial Update: Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

View source ↗

Summary

The update covers Nexavar (sorafenib) as the first targeted therapy in patients with advanced renal cell carcinoma, reporting results from a completed trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Status: COMPLETED